Details about Jörg C. Mahlich

Access statistics for papers by Jörg C. Mahlich.

Last updated 2022-07-13. Update your information in the RePEc Author Service.

Short-id: pma997

Working Papers

2014

1. Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG
   DICE Ordnungspolitische Perspektiven, Heinrich Heine University Düsseldorf, Düsseldorf Institute for Competition Economics (DICE) View citations (1)
   See also Journal Article Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG, Perspektiven der Wirtschaftspolitik, De Gruyter (2015) (2015)

2006

2. The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
   MERIT Working Papers, United Nations University - Maastricht Economic and Social Research Institute on Innovation and Technology (MERIT) View citations (20)
   See also Journal Article The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan, Review of Industrial Organization, Springer (2006) View citations (20) (2006)

2001

3. The Changing Nature of Pharmaceutical R&D - Opportunities for Asia?
   Research Memorandum, Maastricht University, Maastricht Economic Research Institute on Innovation and Technology (MERIT) View citations (1)

Journal Articles

2022

1. Estimation of Health-State Utility Values and Factors Driving Health-Related Quality of Life in People Living with HIV and AIDS and Receiving cART in Germany: Baseline Analysis of a Cohort Study
   Applied Research in Quality of Life, 2022, 17, (2), 851-869

2021

2. Can adaptive clinical trials help to solve the productivity crisis of the pharmaceutical industry? - a scenario analysis
   Health Economics Review, 2021, 11, (1), 1-10

2020

3. Treatment patterns and healthcare resource utilization in palmoplantar pustulosis patients in Japan: A claims database study
   PLOS ONE, 2020, 15, (5), 1-18

2019

4. Patient and Physician Preferences for Therapy Characteristics for Psoriasis: A Discrete Choice Experiment in Japan
   PharmacoEconomics - Open, 2019, 3, (2), 255-264
5. Returns on different types of investment in the global pharmaceutical industry
   Managerial and Decision Economics, 2019, 40, (1), 16-36 View citations (2)

2018

6. Treatment pathways of Japanese prostate cancer patients - A retrospective transition analysis with administrative data
   PLOS ONE, 2018, 13, (4), 1-15

2017

7. Cost of Illness of Japanese Patients with Chronic Lymphocytic Leukemia (CLL), and Budget Impact of the Market Introduction of Ibrutinib
   PharmacoEconomics - Open, 2017, 1, (3), 195-202

2016

8. Determinants of physician's office visits and potential effects of co-payments: evidence from Austria
   International Journal of Health Planning and Management, 2016, 31, (3), e192-e203 View citations (2)

2015

9. Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG
   Perspektiven der Wirtschaftspolitik, 2015, 16, (2), 164-172
   See also Working Paper Vergleichbarkeit internationaler Arzneimittelpreise: Internationale Preisreferenzierung in Deutschland durch das AMNOG, DICE Ordnungspolitische Perspektiven (2014) View citations (1) (2014)

2014

10. Pharmaceutical regulation in Europe and its impact on corporate R&D
    Health Economics Review, 2014, 4, (1), 1-9 View citations (4)

2013

11. Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
    Applied Health Economics and Health Policy, 2013, 11, (5), 509-521 View citations (2)
12. Erratum to: Cost Effectiveness of Paliperidone Palmitate for the Treatment of Schizophrenia in Germany
    Applied Health Economics and Health Policy, 2013, 11, (6), 689-689 View citations (2)
13. Evaluating the concordance of physician judgments and patient preferences on AIDS/HIV therapy - a Discrete Choice Experiment
    Health Economics Review, 2013, 3, (1), 1-11 View citations (1)

2012

14. Economic burden of osteoporotic fractures in Austria
    Health Economics Review, 2012, 2, (1), 1-10 View citations (1)

2011

15. Intangibles Kapital und Rentabilität in der Pharmaindustrie
    Die Unternehmung - Swiss Journal of Business Research and Practice, 2011, 65, (1), 32-49 View citations (1)
16. R&D MANAGEMENT OF JAPANESE PHARMACEUTICAL FIRMS
    International Journal of Innovation and Technology Management (IJITM), 2011, 08, (02), 211-226

2010

17. Patents and performance in the Japanese pharmaceutical industry: An institution-based view
    Asia Pacific Journal of Management, 2010, 27, (1), 99-113 View citations (10)

2006

18. The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan
    Review of Industrial Organization, 2006, 28, (2), 145-164 View citations (20)
    See also Working Paper The Determinants of Pharmaceutical R&D Expenditures: Evidence from Japan, MERIT Working Papers (2006) View citations (20) (2006)

2005

19. Wirtschaftspolitik für wissensintensive Branchen am Beispiel der Pharmaindustrie
    Zeitschrift für Wirtschaftspolitik, 2005, 54, (3), 366-390 View citations (1)

Books

2006

1. Das D-A-CH-Reformbarometer: Reformpolitik in Deutschland, Österreich und der Schweiz, vol 23
   IW-Analysen, Institut der deutschen Wirtschaft (IW) / German Economic Institute

Edited books

2012

1. Korean Science and Technology in an International Perspective
   Springer Books, Springer View citations (4)

2007

2. Innovation and Technology in Korea
   Springer Books, Springer View citations (15)

Chapters

2022

1. Telemedicine in Japan: Challenges and Opportunities
   Springer

2007

2. Introduction: Korea as a Newly Advanced Economy and the Role of Technology and Innovation
   Springer View citations (2)
3. The Technological Competencies of Korea’s Firms: A Patent Analysis
   Springer